Synapse - Works

Results (197)

Immune-related colitis is associated with fecal microbial dysbiosis and can be mitigated by fecal microbiota transplantation

Journal Article

Elkrief, A.; Waters, N. R.; Smith, N.; Dai, A.; Slingerland, J.; Aleynick, N.; Febles, B.; Gogia, P.; Socci, N. D.; Lumish, M.; more...
Cancer Immunology Research (2024)

Fulltext@MSK | Save

High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer

Journal Article

Stonestrom, A. J.; Menghrajani, K. N.; Devlin, S. M.; Franch-Expósito, S.; Ptashkin, R. N.; Patel, S. Y.; Spitzer, B.; Wu, X.; Jee, J.; Vela, P. S.; more...
Blood Advances (2024)

Fulltext@MSK | Save

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Journal Article

Montoya, S.; Bourcier, J.; Noviski, M.; Lu, H.; Thompson, M. C.; Chirino, A.; Jahn, J.; Sondhi, A. K.; Gajewski, S.; Tan, Y. S.; more...
Science (2024)

Fulltext@MSK | Save

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Research Letter

Badar, T.; Nanaa, A.; Atallah, E.; Shallis, R. M.; Guilherme, S. D. C. C.; Goldberg, A. D.; Saliba, A. N.; Patel, A.; Bewersdorf, J. P.; DuVall, A. S.; more...
Blood Cancer Journal (2024)

Fulltext@MSK | Save

Impact of type of hypomethylating agent (HMA) used on outcomes of patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) - A large, multicenter, retrospective analysis

Meeting Abstract

Bewersdorf, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
Blood (2023)

Fulltext@MSK | Save

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) who underwent allogenic stem cell transplantation (HSCT)

Meeting Abstract

Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
Blood (2023)

Fulltext@MSK | Save

Intensive induction chemotherapy vs hypomethylating agents + venetoclax (HMA/VEN) in NPM1-mutant newly diagnosed acute myeloid leukemia (AML) - A multicenter cohort study

Meeting Abstract

Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y. W.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; Lindsley, C.; more...
Blood (2023)

Fulltext@MSK | Save

Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) with missing molecular data

Meeting Abstract

Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
Blood (2023)

Fulltext@MSK | Save

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) who were treated with hypomethylating agents (HMA)

Meeting Abstract

Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
Blood (2023)

Fulltext@MSK | Save

Impact of symptom benefit and transfusion response on survival in myelofibrosis patients treated with pacritinib: PERSIST-2 landmark survival analysis

Meeting Abstract

Ajufo, H.; Bewersdorf, J. P.; Harrison, C. N.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A. T.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
Blood (2023)

Fulltext@MSK | Save